JP2022532998A - 選択的イントロンのスプライシングを調節するための方法及び組成物 - Google Patents

選択的イントロンのスプライシングを調節するための方法及び組成物 Download PDF

Info

Publication number
JP2022532998A
JP2022532998A JP2021563623A JP2021563623A JP2022532998A JP 2022532998 A JP2022532998 A JP 2022532998A JP 2021563623 A JP2021563623 A JP 2021563623A JP 2021563623 A JP2021563623 A JP 2021563623A JP 2022532998 A JP2022532998 A JP 2022532998A
Authority
JP
Japan
Prior art keywords
aic
premrna
selective
therapeutic agent
target protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021563623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532998A5 (cg-RX-API-DMAC10.html
Inventor
アズナレズ,イザベル
Original Assignee
ストーク セラピューティクス,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ストーク セラピューティクス,インク. filed Critical ストーク セラピューティクス,インク.
Publication of JP2022532998A publication Critical patent/JP2022532998A/ja
Publication of JP2022532998A5 publication Critical patent/JP2022532998A5/ja
Priority to JP2025087686A priority Critical patent/JP2025128180A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021563623A 2019-04-26 2020-04-24 選択的イントロンのスプライシングを調節するための方法及び組成物 Pending JP2022532998A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025087686A JP2025128180A (ja) 2019-04-26 2025-05-27 選択的イントロンのスプライシングを調節するための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962839572P 2019-04-26 2019-04-26
US62/839,572 2019-04-26
PCT/US2020/029953 WO2020219977A1 (en) 2019-04-26 2020-04-24 Methods and compositions for modulating splicing of alternative introns

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025087686A Division JP2025128180A (ja) 2019-04-26 2025-05-27 選択的イントロンのスプライシングを調節するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2022532998A true JP2022532998A (ja) 2022-07-21
JP2022532998A5 JP2022532998A5 (cg-RX-API-DMAC10.html) 2023-04-28

Family

ID=72941393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021563623A Pending JP2022532998A (ja) 2019-04-26 2020-04-24 選択的イントロンのスプライシングを調節するための方法及び組成物
JP2025087686A Pending JP2025128180A (ja) 2019-04-26 2025-05-27 選択的イントロンのスプライシングを調節するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025087686A Pending JP2025128180A (ja) 2019-04-26 2025-05-27 選択的イントロンのスプライシングを調節するための方法及び組成物

Country Status (10)

Country Link
US (1) US20220162599A1 (cg-RX-API-DMAC10.html)
EP (1) EP3959313A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022532998A (cg-RX-API-DMAC10.html)
KR (1) KR20220019676A (cg-RX-API-DMAC10.html)
CN (1) CN114127286A (cg-RX-API-DMAC10.html)
AU (1) AU2020263581A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021021384A2 (cg-RX-API-DMAC10.html)
CA (1) CA3134947A1 (cg-RX-API-DMAC10.html)
MX (1) MX2021013081A (cg-RX-API-DMAC10.html)
WO (1) WO2020219977A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023348346A1 (en) * 2022-09-30 2025-03-27 Contera Pharma A/S Antisense oligonucleotides for the treatment of canavan disease
CN121059628A (zh) * 2024-06-03 2025-12-05 时夕(广州)生物科技有限公司 调控RNA剪接的向导agRNA

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019004939A1 (en) * 2017-06-27 2019-01-03 Agency For Science, Technology And Research ANTISENSE OLIGONUCLEOTIDES FOR MODULATING THE FUNCTION OF A LYMPHOCYTE T

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535318A (ja) * 2002-08-12 2005-11-24 ユニヴェルシテ ドゥ シェルブルック プレメッセンジャーrnaのスプライス部位選択の再プログラミング方法
EP3578657B1 (en) * 2010-04-06 2024-03-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
WO2015108907A2 (en) * 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
CN107109411B (zh) * 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
WO2017100587A1 (en) * 2015-12-09 2017-06-15 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof
CN116059236A (zh) * 2015-12-14 2023-05-05 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
CA3013683C (en) * 2016-03-14 2021-07-13 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of pd-l1 expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019004939A1 (en) * 2017-06-27 2019-01-03 Agency For Science, Technology And Research ANTISENSE OLIGONUCLEOTIDES FOR MODULATING THE FUNCTION OF A LYMPHOCYTE T

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NAT. REV. GENET., vol. vol.17, issue 7, JPN6024017928, 2016, pages 407 - 421, ISSN: 0005511059 *
NUCLEIC ACIDS RES., vol. 44, no. 14, JPN6024017927, 2016, pages 6549 - 6563, ISSN: 0005511060 *
OLIGONUCLEOTIDES, vol. 19, no. 1, JPN6024017926, 2009, pages 1 - 13, ISSN: 0005511061 *

Also Published As

Publication number Publication date
BR112021021384A2 (pt) 2021-12-21
EP3959313A4 (en) 2023-09-27
AU2020263581A1 (en) 2021-12-16
KR20220019676A (ko) 2022-02-17
JP2025128180A (ja) 2025-09-02
CN114127286A (zh) 2022-03-01
MX2021013081A (es) 2021-12-10
CA3134947A1 (en) 2020-10-29
EP3959313A1 (en) 2022-03-02
WO2020219977A1 (en) 2020-10-29
US20220162599A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
JP7420679B2 (ja) 状態および疾患の処置のためのアンチセンスオリゴマー
JP2022062140A (ja) 常染色体優性精神遅滞-5とドラベ症候群の処置のためのアンチセンスオリゴマー
JP7049247B2 (ja) 腎臓病の処置のための組成物と方法
JP2022106803A (ja) アラジール症候群の処置のためのアンチセンスオリゴマー
JP7051683B2 (ja) 結節性硬化症の処置のためのアンチセンスオリゴマー
JP6867945B2 (ja) 核内遺伝子出力の標的とされた増強
JP2019500347A (ja) 網膜色素変性症18と網膜色素変性症13の処置のための組成物と方法
JP2025128180A (ja) 選択的イントロンのスプライシングを調節するための方法及び組成物
JP7660515B2 (ja) 病態及び疾患の治療用アンチセンスオリゴマー
RS58573B1 (sr) Antisensna nukleinska kiselina
SA518400251B1 (ar) أوليجومرات في اتجاه مضاد للنسخ وطرق استخدامها لعلاج أمراض مرتبطة بجين حمض ألفا-جلوكوسيداز
JP5559159B2 (ja) 修飾オリゴヌクレオチドを使用するhrp−3の阻害
AU2023237229A1 (en) Methods of treating glaucoma.
US20240254488A1 (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
EP3984553A1 (en) Composition for preventing or treating cancer
US20170096670A1 (en) Dna aptamers specific to cd200r1 and their therapeutic uses
TW202430635A (zh) 用於抑制補體成分C3(C3)表現之RNAi藥劑、其醫藥組合物及使用方法
EA049459B1 (ru) Способы и композиции для модуляции сплайсинга и трансляции

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250127